You are here: Home
Business
Investment
Lee Byers Downgrades BioMimetic Therapeutics (BMTI) to Neutral
Lee Byers Downgrades BioMimetic Therapeutics (BMTI) to Neutral
Lee Byers downgraded BioMimetic Therapeutics (NASDAQ: BMTI) from Overweight to Neutral with a $5 price target.
FOR IMMEDIATE RELEASE
(Free-Press-Release.com) July 29, 2011 --
Shares of BioMimetic Therapeutics closed at $5.12 yesterday, with a 52 week range of $4.99-$14.80.
Located in Franklin, Tennessee, BioMimetic Therapeutics (NASDAQ: BMTI) specializes in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedic surgery and sports medicine applications.
All Augment branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB) platform technology, which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments.
Dr. Samuel Lynch, BioMimetic's president, CEO and founder, conducted research on the role of PDGF in tissue repair and regeneration while on staff at Harvard beginning in the mid 1980s. These efforts generated a foundation of scientific knowledge and intellectual property from which BioMimetic Therapeutics is now based
BioMimetic s BioMimetic Therapeutics Biotech Biotechnology ceo medicine Samuel Lynch technology

Where: Paris,France
Industry: Business Services
Where: Hong Kong,Hong Kong (China)
Industry:
Where: Amman,Jordan
Industry:
Post your news to the World.See you news here immediately. It's easy and free!
Create free account or Login.


